A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2017
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C; Liver cirrhosis
- Focus Therapeutic Use
- Sponsors AbbVie
- 31 Jul 2017 Planned End Date changed from 15 Oct 2018 to 10 Oct 2018.
- 31 May 2017 Planned End Date changed from 11 Oct 2018 to 15 Oct 2018.
- 28 Apr 2017 Status changed from not yet recruiting to recruiting.